New aspects in the treatment of neovascular age-related macular degeneration: Current position of the Retinological Society, the German Ophthalmological Society, and the Professional Association of Ophthalmologists in Germany (as of March 2009);Neue Aspekte in der Therapie der neovaskul̈ren altersabḧngigen Makuladegeneration: Aktuelle Stellungnahme der Retinologischen Gesellschaft, der Deutschen Ophthalmologischen Gesellschaft und des Berufsverbands der Augen̈rzte Deutschlands e.V. (Stand: M̈rz 2009)

Ophthalmologe

Volumn 106, Issue 5, 2009, Pages 457-464

[No Author Info available]

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOGENESIS INHIBITOR;

ARTICLE; CLINICAL PRACTICE; GERMANY; HUMAN; MEDICAL SOCIETY; METHODOLOGY; NEOVASCULAR GLAUCOMA; PHOTOCHEMOTHERAPY; PRACTICE GUIDELINE; RETINA MACULA DEGENERATION; STANDARD;

ANGIOGENESIS INHIBITORS; GERMANY; GLAUCOMA, NEOVASCULAR; HUMANS; MACULAR DEGENERATION; PHOTOCHEMOTHERAPY; PHYSICIAN'S PRACTICE PATTERNS; PRACTICE GUIDELINES AS TOPIC; SOCIETIES, MEDICAL;

EID: 70149115283     PISSN: 0941293X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00347-009-1969-2     Document Type: Article

References (51)

1. http://www.controlled-trials.com/ISRCTN92166560.
2. http://www.pharmakologie-bremen.de/index.php/klinische-forschung/vibera.
3. http://www.clinicaltrials.gov/ct2/show/NCT00559715.
4. http://www.med.upenn.edu/cpob/studies/CATT.shtml.
5. Stellungnahme zu aktuellen therapeutischen Möglichkeiten bei der neovaskulären altersabhängigen Makuladegeneration (2006) Klin Monatsbl Augenheilkd 223:271-278.
6. http://www.dog.org/publikationen/DOG_Empfehlung_Intravitreale_Injektione n.pdf.
7. Aktuelle therapeutische Möglichkeiten bei der neovaskulären altersabhängigen Makuladegeneration. Stellungnahme der Retinologischen Gesellschaft, der Deutschen Ophthalmologischen Gesellschaft und des Berufsverbands der Augenärzte Deutschlands zu aktuellen therapeutischen Möglichkeiten bei der neovaskulären altersabhängigen Makuladegeneration (2007) Ophthalmologe 104:628-634.
8. Stellungnahme der Retinologischen Gesellschaft, der Deutschen Ophthalmologischen Gesellschaft und des Berufsverbands der Augenärzte Deutschlands zu aktuellen therapeutischen Moglichkeiten bei der neovaskulären altersabhängigen Makuladegeneration (2007) Klin Monatsbl Augenheilkd 224:559-566.
9. http://library.corporate-ir.net/library/11/119/119576/items/309061/Final 2_0508_Week52_Website_Slides_9-26-08.pdf.
10. OPKO Health announces completion of enrollment for Its phase III clinical trial of bevasiranib for treatment of AMD (2008) investor.opko.com/releasedetail.cfm?ReleaseID=352313.
11. http://www.nice.org.uk/TA155.
12. Aiello LP, Brucker AJ, Chang S et al (2004) Evolving guidelines for intravitreous injections. Retina 24:S3-S19.
13. Alexander SL, Linde-Zwirble WT, Werther W et al (2007) Annual rates of arterial thromboembolic events in medicare neovascular age-related macular degeneration patients. Ophthalmology 114:2174-2178.
14. Angulo Bocco MC, Glacet-Bernard A, Zourdani A et al (2008) Injection intravitréenne: Évaluation rétrospective de la technique et des complications d'une serie de 2028 injections. J Fr Ophtalmol 31:693-698.
15. Antoszyk AN, Tuomi L, Chung CY et al (2008) Ranibizumab combined with verteporfin photodynamic therapy in neovascular age-related macular degeneration (FOCUS): year 2 results. Am J Ophthalmol 145:862-874.
16. Brown DM, Kaiser PK, Michels M et al (2006) Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med 355:1432-1444.
17. Chakravarthy U, Adamis AP, Cunningham ET Jr et al (2006) Year 2 efficacy results of 2 randomized controlled clinical trials of pegaptanib for neovascular age-related macular degeneration. Ophthalmology 113:1508-1521.
18. Chappelow AV, Kaiser PK (2008) Neovascular age-related macular degeneration: Potential therapies. Drugs 68:1029-1036.
19. Colquitt JL, Jones J, Tan SC et al (2008) Ranibizumab and pegaptanib for the treatment of age-related macular degeneration: A systematic review and economic evaluation. Health Technol Assess 12:iii-iv, ix-201.
20. Dafer RM, Schneck M, Friberg TR et al (2007) Intravitreal ranibizumab and bevacizumab: A review of risk. Semin Ophthalmol 22:201-204.
21. Dejneka NS, Wan S, Bond OS et al (2008) Ocular biodistribution of bevasiranib following a single intravitreal injection to rabbit eyes. Mol Vis 14:997-1005.
22. Dierks C, Nitz G (2008) Rechtsfortbildung dank Lucentis? Gesellschaftspolitische Kommentare 11:3-7.
23. Farah SE (2008) Treatment of neovascular age-related macular degeneration with pegaptanib and boosting with bevacizumab or ranibizumab as needed. Ophthalmic Surg Lasers Imaging 39:294-298.
24. Fintak DR, Shah GK, Blinder KJ et al (2008) Incidence of endophthalmitis related to intravitreal injection of bevacizumab and ranibizumab. Retina 28:1395-1399.
25. Francke R, Hart D (2003) Off label use - Arzneimittelrechtliche, haftungsrechtliche, berufsrechtliche und sozialrechtliche Fragen. Die Sozialgerichtsbarkeit 50:653-664.
26. Gamulescu MA, Framme C, Sachs H (2007) RPE-rip after intravitreal bevacizumab (Avastin) treatment for vascularised PED secondary to AMD. Graefes Arch Clin Exp Ophthalmol 245:1037-1040.
27. Gragoudas ES, Adamis AP, Cunningham ET Jr et al (2004) Pegaptanib for neovascular age-related macular degeneration. N Engl J Med 351:2805-2816.
28. Hart D (2008) Arzthaftung und off label use. Information, Standard und Zulassung. In: Medizinrecht DAA (Hrsg) Medizinrecht heute: Erfahrungen, Analysen, Entwicklungen. Festschrift: 10 Jahre Arbeitsgemeinschaft Medizinrecht im DAW: Deutscher Anwaltverlag 173-190.
29. Hart D (2008) Off-Label-Use von Arzneimitteln: Hintergründe und Lösungsansätze eines vielschichtigen Problems. Arzneimittelbrief 42:81-96.
30. Heimes B, Lommatzsch A, Zeimer M et al (2008) Foveal RPE autofluorescence as a prognostic factor for anti-VEGF therapy in exudative AMD. Graefes Arch Clin Exp Ophthalmol 246:1229-1234.
31. Hughes MS, Sang DN (2006) Safety and efficacy of intravitreal bevacizumab followed by pegaptanib maintenance as a treatment regimen for age-related macular degeneration. Ophthalmic Surg Lasers Imaging 37:446-454.
32. Ip MS, Scott IU, Brown GC et al (2008) Anti-vascular endothelial growth factor pharmacotherapy for age-related macular degeneration: A report by the American Academy of Ophthalmology. Ophthalmology 115:1837-1846.
33. Kleinman ME, Yamada K, Takeda A et al (2008) Sequence- and target-independent angiogenesis suppression by siRNA via TLR3. Nature 452:591-597.
34. Kook D, Wolf A, Neubauer AS et al (2008) Retinale Pigmentepithelrisse nach intravitrealem Bevacizumab bei AMD. Häufigkeit und Verlauf. Ophthalmologe 105:158-164.
35. Lommatzsch AP, Heimes B, Gutfleisch M et al (2008) Die Therapie der vaskularisierten serosen Pigmentepithelabhebung bei AMD - Beobachtungen nach Wechsel des intravitrealen Medikamentes bei Therapieversagen. Klin Monatsbl Augenheilkd 874-879.
36. Macular Photocoagulation Study Group (1991) Argon laser photocoagulation for neovascular maculopathy. Five-year results from randomized clinical trials. Arch Ophthalmol 109:1109-1114.
37. Meyer CH, Mennel S, Eter N (2007) Endophthalmitisrate mit und ohne topische postoperative Antibiotikagabe nach intravitrealer Avastin-injektion. Ophthalmologe 104:952-957.
38. Nguyen QD, Shah SM, Hafiz G et al (2006) A phase I trial of an IV-administered vascular endothelial growth factor trap for treatment in patients with choroidal neovascularization due to age-related macular degeneration. Ophthalmology 113:1522 e1521-1522 e1514.
39. Novartis NSO, Basel CH (2008) Investigator Notification for ranibizumab: Lucentis Meta-Analysis.
40. Novartis Pharma GmbH (2008) Fachinformation Lucentis® (Stand August 2008). Rote Liste GmbH.
41. Regillo CD, Brown DM, Abraham P et al (2008) Randomized, double-masked, sham-controlled trial of ranibizumab for neovascular age-related macular degeneration: PIER Study year 1. Am J Ophthalmol 145:239-248.
42. http://www.pei.de/SharedDocs/Downloads/fachkreise/rhb/09-02-11-rhb-avast in,templateId=raw,property=publicationFile.pdf/09-02-11-rhb-avastin.pdf.
43. Rosenfeld PJ, Brown DM, Heier JS et al (2006) Ranibizumab for neovascular age-related macular degeneration. N Engl J Med 355:1419-1431.
44. Schmidt-Erfurth U, Wolf S (2008) Same-day administration of verteporfin and ranibizumab 0.5 mg in patients with choroidal neovascularisation due to age-related macular degeneration. Br J Ophthalmol 92:1628-1635.
45. Schmidt-Erfurth UM, Richard G, Augustin A et al (2007) Guidance for the treatment of neovascular age-related macular degeneration. Acta Ophthalmol Scand 85:486-494.
46. Schouten JS, La Heij EC, Webers CA et al (2009) A systematic review on the effect of bevacizumab in exudative age-related macular degeneration. Graefes Arch Clin Exp Ophthalmol 247:1-11.
47. Scott IU, Flynn HW Jr (2007) Reducing the risk of endophthalmitis following intravitreal injections. Retina 27:10-12.
48. Singerman LJ, Masonson H, Patel M et al (2008) Pegaptanib sodium for neovascular age-related macular degeneration: Third-year safety results of the VEGF Inhibition Study in Ocular Neovascularisation (VISION) trial. Br J Ophthalmol 92:1606-1611.
49. Weinberger AW, Thiel M, Mohammadi B et al (2007) Retinal pigment epithelium tears after intravitreal bevacizumab in pigment epithelium detachment. Am J Ophthalmol 144:294-296.
50. http://www.eprints.hta.lbg.ac.at/718/1/Rapid_Assessment_002.pdf.
51. Wu L, Martinez-Castellanos MA, Quiroz-Mercado H et al (2008) Twelve-month safety of intravitreal injections of bevacizumab (Avastin(R)): Results of the Pan-American Collaborative Retina Study Group (PACORES). Graefes Arch Clin Exp Ophthalmol 246:81-87.